Sex: F
Vaccine: COVID19
Symptoms: Body mass index, COVID-19, SARS-CoV-2 test
Clinical narrative: Positive test for SARS Cov2; This spontaneous case was reported by a non-health professional and describes the occurrence of COVID-19 (Positive test for SARS Cov2) in a female patient of an unknown age who received mRNA-1273.815 (SPIKEVAX 2023-2024) (batch no. 8058856) for COVID-19 prophylaxis.     The patient's past medical history included Hysterectomy (S/P hysterectomy with oophorectomy) on 25-Jul-2022, Oophorectomy (S/P hysterectomy with oophorectomy) on 25-Jul-2022 and Discectomy with spinal fusion (S/P cervical spinal fusion-Fusion spine Anterior cervical and Discectomy C5-C6, C6-C7, Anterior cervical discectomy fusion Jun-2023) on 15-Sep-2023. Previously administered products included for Product used for unknown indication: Hepatitis A, adult on 08-Feb-2001, IPV (Subcutaneous) on 08-Feb-2001, YELLOW FEVER (SUBCUTANEOUS) on 14-Feb-2001, TYPHOID INACTIVATED on 14-Feb-2001, Hepatitis A, adult on 16-Aug-2001, PNEUMOCOCCAL CONJUGATE 7-VALENT on 25-Jan-2007, TDAP on 07-Sep-2018, FLUBLOK RIV4 on 29-Nov-2019, Pfizer/BioNTech COVID-19 Vaccine (LOT: EW0167, Route: Intramuscular (Dose 1)) on 29-Apr-2021, Pfizer/BioNTech COVID-19 Vaccine (LOT: EW0183, Route: Intramuscular (Dose 2)) on 20-May-2021, INFLUENZA on 21-Oct-2021, Pfizer/BioNTech COVID-19 Vaccine (LOT: FH8757, Route: Intramuscular (Dose 3)) on 14-Dec-2021, ZOSTER RECOMBINANT on 28-Mar-2022, Pfizer/BioNTech COVID-19 Vaccine (LOT: GJ5342, Route: Intramuscular (Dose 4)) on 23-Apr-2022, ZOSTER RECOMBINANT on 25-May-2022, Pfizer/BioNTech COVID-19 Vaccine (LOT: GJ5342, Route: Intramuscular (Dose 5)) on 26-Sep-2022, FLUCELVAX PF on 27-Sep-2022, RSV and RECOMBINANT (AREXVY) on 12-Nov-2023. Past adverse reactions to the above products included No adverse effect with FLUBLOK RIV4, FLUCELVAX PF, Hepatitis A, adult, Hepatitis A, adult, INFLUENZA, IPV (Subcutaneous), PNEUMOCOCCAL CONJUGATE 7-VALENT, Pfizer/BioNTech COVID-19 Vaccine, Pfizer/BioNTech COVID-19 Vaccine, Pfizer/BioNTech COVID-19 Vaccine, Pfizer/BioNTech COVID-19 Vaccine, Pfizer/BioNTech COVID-19 Vaccine, RSV, RECOMBINANT (AREXVY), TDAP, TYPHOID INACTIVATED, YELLOW FEVER (SUBCUTANEOUS), ZOSTER RECOMBINANT and ZOSTER RECOMBINANT. Concurrent medical conditions included Obesity, Non-smoker, Mixed hyperlipidemia, Microscopic hematuria since 22-Mar-2022, Hypermetropia since 15-May-2022, Duodenitis since 18-May-2022, Generalized anxiety disorder since 27-May-2022, Low back pain since 22-Jun-2023, Cervical myelopathy since 26-Jun-2023, Cervical radiculopathy since 26-Jun-2023, Cold sores since 24-Oct-2023, Aortic regurgitation since 07-Dec-2023, Allergy to lanolin (Lanolin), Allergy (Persil detergent (other)), Reaction to preservatives (Sulfites), Topical adhesive allergy (Adhesive), Drug allergy (Ibuprofen), Drug allergy (Progestins) and Allergy (Cigarette smoke). Concomitant products included FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]) for Rhinitis, AMOXICILLIN (AMOXIL [AMOXICILLIN]), AZELASTINE HYDROCHLORIDE (ASTELIN [AZELASTINE HYDROCHLORIDE]), BACLOFEN (LIORESAL), LOSARTAN POTASSIUM (COZAAR), METHYLPREDNISOLONE (MEDROL DOSEPAK), MEXILETINE HYDROCHLORIDE (MEXITIL), MONTELUKAST SODIUM (SINGULAIR), NALOXONE HYDROCHLORIDE (NARCAN), PANTOPRAZOLE SODIUM SESQUIHYDRATE (PROTONIX [PANTOPRAZOLE SODIUM SESQUIHYDRATE]) and PREGABALIN (LYRICA) for an unknown indication.    On 30-Oct-2023, the patient received sixth dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On 24-Jan-2024,  after starting mRNA-1273.815 (SPIKEVAX 2023-2024), the patient experienced COVID-19 (Positive test for SARS Cov2). At the time of the report, COVID-19 (Positive test for SARS Cov2) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-May-2022, Body mass index: 33.0-33.9, ADULT. On 24-Jan-2024, SARS-CoV-2 test: Positive.   The patient had Influenza Quad PF on 15-Sep-2023, Influenza Quad w/Preservative on 13-Oct-2018, Influenza TIV 3 yrs+ on 15-Oct-2002, 14-Oct-2003, 19-Oct-2004, 05-Dec-2005, 26-Dec-2006 and 02-Oct-2008, Influenza Whole Historical on 08-Nov-2001, Influenza Split (Inc. purified surface antigen) on 14-Nov-2007 and 17-Feb-2010 and Novel Influenza-H1N1 PF inj on 17-Feb-2010.  It was unknown if the patient had any specific test for thromboembolic events with thrombocytopenia.  No treatment information was provided.